Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists who Treat Hematologic Malignancies (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 24, 2008
OK, now that we know why how can we prevent the reactions to increase utilization of BMS & Imclone's Erbitux?
Analysis of: Researchers Find Cause of Severe Allergic Reaction to Cancer Drug | pharmalive.com
Author: GLG Expert Contributor
Antibodies have been identified that explain allergic reactions that can terminate it's use in individuals who "react."
March 24, 2008
GSK has a monoclonal antibody (Mepolizumab) that can treat patients with "hypereosinophilia.)
Analysis of: Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab | content.nejm.org
Author: GLG Expert Contributor
This exceedingly rare condition produces organ damage due to infiltration of blood eosinophils. Steroids are the only effective therapy in the non myeloproliferative subset of patients, so for the chosen few this drug will be invaluable.
March 20, 2008
Lung cancer vaccination: a kinder, gentler (sic) therapy?? We will see..
Analysis of: Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Vaccination with EGF was used in a maintenance situation after initial chemo. No only did it produce EGF antibodies BUT the antibody response was correlated with survival!!
March 20, 2008
Revlimid in non-myeloma malignancies? A review article? It's time is coming!
Analysis of: Lenalidomide for the Treatment of B-Cell Malignancies | jco.ascopubs.org
Author: GLG Expert Contributor
Revlimid has significant activity in non Hodgkin's lymphomas (NHL)as well as chronic lymphatic leukemia (CLL) although why is somewhat unclear.
March 19, 2008
Avastin (Genentech) a double edged sword?
Analysis of: Doctors See How Cancer Drug Can Damage Kidneys | www.washingtonpost.com
Author: GLG Expert Contributor
Avastin, an antiangiogenic agent used in cancer and other disorders, may have more side effects than originally recognized including proteinuria as well as kidney damage.
March 17, 2008
Genzyme's Cerezyme: When is enough enough
Analysis of: Cutting Dosage of Costly Drug Spurs a Debate | www.nytimes.com
Author: GLG Expert Contributor
Pharma recommends more drug than may actually be needed. This does not apply just to Cerezyme, but the Epo products (Amgen & J&J), Avastin (Genentech.)
March 17, 2008
Fraud: Inevitable no matter who is in charge
Analysis of: 5 Guilty of Fraud in Health Care Finance | www.nytimes.com
Author: GLG Expert Contributor
Prison terms to be handed out for fraud by a health care financing firm. Go figure?
March 14, 2008
The FDA givith (Amgen's Nplate) and takith away (Amgen's Aranesp)
Analysis of: Platelet Treatment Wins FDA Panel's Support | online.wsj.com
Author: GLG Expert Contributor
This is an agent, approved for use with restrictions, in ITP.
March 14, 2008
FDA & Epo: Not as bad as expected!
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits | online.wsj.com
Author: GLG Expert Contributor
Epo products (Aranesp, Procrit, Epogen) from Amgen and J & J will be restricted to some degree with control of hemoglobin levels, NO use in curable malignancies ..." the panel voted 11 to 2 in recommending that the drugs not be used in cancer patients who are likely to be cured from their...
March 14, 2008
Nplate: An effective parenteral therapy for refractory chronic ITP
Analysis of: Platelet Treatment Wins FDA Panel's Support | online.wsj.com
Author: GLG Expert Contributor
FDA panel recommned approval of Amgen's Nplate for patients with refractory/recurrent chronic ITP who have failed other therapies like steroids, immunoglobulins, Rituximab and spleenectomy. The safety/efficacy profile was favorable for this relatively narrow indication, although long term safet issues...

Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Next151 to 160 of 702

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T21:45:18.380